Xanomeline and trospium chloride (KarXT)

DRUG3 trials

Sponsors

Bristol-Myers Squibb, New York State Psychiatric Institute, Zai Lab (Shanghai) Co., Ltd.

Conditions

SCHIZOPHRENIA 1 (Disorder)Schizoaffecitve DisorderSchizophreniaSchizophrenia Disorder

Phase 1

A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

RecruitingNCT07423546

New York State Psychiatric InstituteSchizoaffecitve Disorder, SCHIZOPHRENIA 1 (Disorder)

Start: 2026-07-01End: 2027-12-31Target: 12Updated: 2026-07-14

Unknown Phase

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

RecruitingNCT07379827

Bristol-Myers SquibbSchizophrenia

Start: 2026-02-26End: 2028-06-20Target: 1500Updated: 2026-08-19

A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia

Not yet recruitingNCT07802132

Zai Lab (Shanghai) Co., Ltd.Schizophrenia Disorder

Start: 2026-09-20End: 2028-12-31Target: 250Updated: 2026-09-03